Delivering adjuvant chemotherapy to women with early‐stage breast carcinoma

Variations in practice patterns are markers for the quality of patient care in general medicine, but little is known about variation in care delivered to cancer patients. This study's purpose was to describe chemotherapy use, variations in chemotherapy delivery, and the incidence of complications in community practice settings.

[1]  M. Extermann,et al.  Measuring comorbidity in older cancer patients. , 2000, European journal of cancer.

[2]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[3]  D. Wickerham,et al.  Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Richel,et al.  Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy , 1999 .

[5]  J. Wennberg,et al.  Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. , 1999, JAMA.

[6]  R. Vollmer.  Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. , 1999, Journal of the National Cancer Institute.

[7]  D. Richel,et al.  Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  W. Hryniuk,et al.  A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D A Berry,et al.  Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. , 1998, Journal of the National Cancer Institute.

[10]  D. Tu,et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Silber,et al.  First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Gurwitz,et al.  Age-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Wickerham,et al.  Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[16]  G. Bonadonna,et al.  Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. , 1995, JAMA.

[17]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[18]  J. Jollis,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. , 1993, Journal of clinical epidemiology.

[19]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[20]  Anthony Howell,et al.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992 .

[21]  Anna L. Brown,et al.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[23]  M. Zelen,et al.  Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[24]  G. Bonadonna,et al.  Adjuvant chemotherapy after conservative surgery plus irradiation versus modified radical mastectomy. Analysis of drug dosing and toxicity. , 1987, The American journal of medicine.

[25]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[26]  M. Levine,et al.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Raab,et al.  Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  G. Bonadonna,et al.  Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  G. Hortobagyi,et al.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy. , 1979, Cancer research.

[31]  J. Bull,et al.  A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy , 1978, Cancer.